Æterna Zentarisの資本の返還
Æterna Zentarisの資本の返還は何ですか。
Æterna Zentaris, Inc.の資本の返還は-83.44%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
TSXのセクタHealth Careにおける資本の返還の企業と比べるÆterna Zentaris
Æterna Zentarisは何をしますか。
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Æterna Zentarisと類似の資本の返還
- Galectoの資本の返還は-83.73%です。
- CAP-XXの資本の返還は-83.71%です。
- Cytocom Incの資本の返還は-83.71%です。
- ASLAN Pharmaceuticals Ltdの資本の返還は-83.58%です。
- Aptorumの資本の返還は-83.53%です。
- iDreamSky Technologyの資本の返還は-83.50%です。
- Æterna Zentarisの資本の返還は-83.44%です。
- Patrysの資本の返還は-83.39%です。
- good natured Productsの資本の返還は-83.25%です。
- Gold Mountainの資本の返還は-83.21%です。
- FranceSoir e SAの資本の返還は-83.19%です。
- Tiger Resource Plcの資本の返還は-83.11%です。
- Greenlane Renewablesの資本の返還は-82.95%です。